$传奇生物(LEGN)$ $Arcellx(ACLX)$ Arcellx and Legend Biotech traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of minimal residual disease and complete response as study endpoints that can support accelerated approval of treatments for multiple myeloma, a rare blood cancer.